As interest in the cancer-fighting potential of radiopharmaceutical drugs continues to swell, companies have unleashed a spate of investments in recent years to manufacture the nuclear medicines an | ...
Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...
ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...
Last week, the company got the FDA's tentative approval for the radioligand therapy, but a judge may soon decide whether it's ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.
A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...
Pharmacokinetic analysis revealed sustained activity at 15 days, a finding corroborated by imaging that demonstrated prolonged tumor retention of the therapeutic agent. Importantly, researchers found ...
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results